Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% 95% CI, 23.1 to 50.2 and 20.8 months IQR, 7.6-not reached, respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% 95% CI, 28.5 to 60.2 and 28.3 months IQR, 9.2-not reached, respectively) than the six patients expressing type 2 (0% 95% CI, 0 to 45.9 and 7.5 months IQR, 3.9-not reached, respectively, PFS HR, 3.2 95% CI, 1.01 to 10.2). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.